Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: A consensus-based SIE, SIES, GITMO position paper

Leukemia Research

Volumn 38, Issue 2, 2014, Pages 155-160

  Barosi, Giovanni ^a   Vannucchi, Alessandro M ^b   De Stefano, Valerio ^c   Pane, Fabrizio ^d   Passamonti, Francesco ^e   Rambaldi, Alessandro ^f   Saglio, Giuseppe ^g   Barbui, Tiziano ^f   Tura, Sante ^h  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^e OSPEDALE DI CIRCOLO   (Italy)

^f General and Emergency Surgery department   (Italy)

^g UNIVERSITY OF TURIN   (Italy)

^h UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Essential thrombocythemia; Myelofibrosis; Myeloproliferative neoplasm; Polycythemia vera; Unmet clinical need

Indexed keywords

ACETYLSALICYLIC ACID; PLACEBO; RUXOLITINIB; JAK2 PROTEIN, HUMAN; JANUS KINASE 2;

ARTICLE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CYTOREDUCTIVE SURGERY; DIAGNOSTIC ACCURACY; DISEASE MARKER; DRUG APPROVAL; DRUG EFFICACY; DRUG RESPONSE; GENE; GENE MUTATION; HISTOLOGY; HUMAN; JAK2V617F GENE; MUTATIONAL ANALYSIS; MYELOFIBROSIS; MYELOPROLIFERATIVE NEOPLASM; PHILADELPHIA NEGATIVE MYELOPROLIFERATIVE NEOPLASM; PHLEBOTOMY; POLYCYTHEMIA VERA; PREFIBROTIC MYELOFIBROSIS; PRIORITY JOURNAL; RELIABILITY; SPLACHNIC VEIN THROMBOSIS; SPLENECTOMY; THROMBOCYTHEMIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT INDICATION; VEIN THROMBOSIS; AGED; AMINO ACID SUBSTITUTION; CLASSIFICATION; CONSENSUS; CONSENSUS DEVELOPMENT; EXPERT WITNESS; FEMALE; GENETICS; HEALTH CARE DELIVERY; HEALTH SERVICE; MALE; MEDICAL SOCIETY; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; PHILADELPHIA 1 CHROMOSOME; UNCERTAINTY; VERY ELDERLY; WORLD HEALTH ORGANIZATION;

AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; CONSENSUS; EXPERT TESTIMONY; FEMALE; HEALTH SERVICES ACCESSIBILITY; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; PHILADELPHIA CHROMOSOME; SOCIETIES, MEDICAL; UNCERTAINTY; WORLD HEALTH ORGANIZATION;

EID: 84892491761     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.09.008     Document Type: Article

References (52)

1. Visser O., Trama A., Maynadié M., Stiller C., Marcos-Gragera R., De Angelis R., et al. Incidence, survival and prevalence of myeloid malignancies in Europe. Eur J Cancer 2012, 48(17):3257-3266.
2. Klampfl T., Harutyunyan A., Berg T., Gisslinger B., Schalling M., Bagienski K., et al. Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Blood 2011, 118(1):167-176.
3. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, IARC, Lyon. S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein (Eds.).
4. Barosi G., Mesa R., Finazzi G., Harrison C., Kiladjian J.J., Lengfelder E., et al. Revised response criteria for polycythemia vera and essential thrombocythemia: a ELN and IWG-MRT consensus project. Blood 2013, 121(23):4778-4781.
5. Tefferi A., Cervantes F., Mesa R., Passamonti F., Verstovsek S., Vannucchi A.M., et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European LeukemiaNet (ELN) Consensus Report. Blood 2013, [Epub ahead of print].
6. Delbecq A.L., van de Ven A.H., Gustafson D.H. Group techniques for program planning: a guide to nominal group and Delphi processes 1975, Scott, Foresman and Co., Glenview, IL.
7. Tefferi A., Vardiman J.W. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008, 22(1):14-22.
8. Spivak J.L., Silver R.T. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood 2008, 112(2):231-239.
9. Harrison C. Rethinking disease definitions and therapeutic strategies in essential thrombocythemia and polycythemia vera. Hematol Am Soc Hematol Educ Program 2010, 2010:129-134.
10. Thiele J., Kvasnicka H.M., Tefferi A., Barosi G., Orazi A., Vardiman J.W. Primary myelofibrosis. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, 44-47. IARC, Lyon. S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein (Eds.).
11. Wilkins B.S., Erber W.N., Bareford D., Buck G., Wheatley K., East C.L., et al. Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood 2008, 111(1):60-70.
12. Buhr T., Hebeda K., Kaloutsi V., Porwit A., Van der Walt J., Kreipe H. European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica 2012, 97(3):360-365.
13. Koopmans S.M., Bot F.J., Lam K.H., van Marion A.M., de Raeve H., Hebeda K.M. Reproducibility of histologic classification in nonfibrotic myeloproliferative neoplasia. Am J Clin Pathol 2011, 136(4):618-624.
14. Brousseau M., Parot-Schinkel E., Moles M.P., Boyer F., Hunault M., Rousselet M.C. Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis. Histopathology 2010, 56(6):758-767.
15. Thiele J., Orazi A., Kvasnicka H.M., Franco V., Boveri E., Gianelli U., et al. European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica 2012, 97(3):360-365.
16. Thiele J., Kvasnicka H.M., Müllauer L., Buxhofer-Ausch V., Gisslinger B., Gisslinger H. Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. Blood 2011, 117(21):5710-5718.
17. Corazza G.R., Bonvicini F., Frazzoni M., Gatto M., Gasbarrini G. Observer variation in assessment of jejunal biopsy specimens. A comparison between subjective criteria and morphometric measurement. Gastroenterology 1982, 83(6):1217-1222.
18. Ohshima K., Kikuchi M., Takeshita M. A megakaryocyte analysis of the bone marrow in patients with myelodysplastic syndrome, myeloproliferative disorder and allied disorders. J Pathol 1995, 177(2):181-189.
19. Chait Y., Condat B., Cazals-Hatem D., Rufat P., Atmani S., Chaoui D., et al. Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis. Br J Haematol 2005, 129(4):553-560.
20. Barosi G., Buratti A., Costa A., Liberato L.N., Balduini C., Cazzola M., et al. An atypical myeloproliferative disorder with high thrombotic risk and slow disease progression. Cancer 1991, 68(10):2310-2318.
21. De Stefano V., Teofili L., Leone G., Michiels J.J. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis. Semin Thromb Hemost 1997, 23(5):411-418.
22. Primignani M., Barosi G., Bergamaschi G., Gianelli U., Fabris F., Reati R., et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology 2006, 44(6):1528-1534.
23. Dentali F., Squizzato A., Brivio L., Appio L., Campiotti L., Crowther M., et al. JAK2V617F mutation for the early diagnosis of Ph-myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood 2009, 113(22):5617-5623.
24. Kiladjian J.J., Cervantes F., Leebeek F.W., Marzac C., Cassinat B., Chevret S., et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood 2008, 111(10):4922-4929.
25. Barbui T., Barosi G., Birgegard G., Cervantes F., Finazzi G., Griesshammer M., et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011, 29(6):761-770.
26. Marchioli R., Finazzi G., Landolfi R., Kutti J., Gisslinger H., Patrono C., et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 2005, 23(10):2224-2232.
27. Barbui T., Thiele J., Carobbio A., Passamonti F., Rumi E., Randi M.L., et al. Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis. Blood 2012, 120(3):569-571.
28. Barbui T., Finazzi G., Carobbio A., Thiele J., Passamonti F., Rumi E., et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 2012, 120(26):5128-5133.
29. Campbell P.J., Scott L.M., Buck G., Wheatley K., East C.L., Marsden J.T., et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005, 366(9501):1945-1953.
30. Landolfi R., Marchioli R., Kutti J., Gisslinger H., Tognoni G., Patrono C., et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004, 350(2):114-124.
31. Cervantes F., Dupriez B., Pereira A., Passamonti F., Reilly J.T., Morra E., et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009, 113(13):2895-2901.
32. Passamonti F., Cervantes F., Vannucchi A.M., Morra E., Rumi E., Pereira A., et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010, 115(9):1703-1708.
33. Gangat N., Caramazza D., Vaidya R., George G., Begna K., Schwager S., et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011, 29(4):392-397.
34. Guglielmelli P., Biamonte F., Score J., Hidalgo-Curtis C., Cervantes F., Maffioli M., et al. EZH2 mutational status predicts poor survival in myelofibrosis. Blood 2011, 118(19):5227-5234.
35. Vannucchi A.M., Lasho T.L., Guglielmelli P., Biamonte F., Pardanani A., Pereira A., et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013, [Epub ahead of print].
36. Verstovsek S., Mesa R.A., Gotlib J., Levy R.S., Gupta V., DiPersio J.F., et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012, 366:799-807.
37. Harrison C., Kiladjian J-J., Al-Ali H.K., Gisslinger H., Waltzman R., Stalbovskaya V., et al. JAK inhibition with Ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012, 366:787-798.
38. Tefferi A., Litzow M.R., Pardanani A. Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med 2011, 365(15):1455-1457.
39. Verstovsek S., Kantarjian H.M., Estrov Z., Cortes J.E., Thomas D.A., Kadia T., et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood 2012, 120(6):1202-1209.
40. Cervantes F., Kiladjian J.-J., Niederwieser D., Sirulnik A., Stalbovskaya V., McQuity M., et al. Long-term safety, efficacy, and survival findings from Comfort-II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts) 2012, 120(Nov):801.
41. Guyatt G.H., Oxman A.D., Vist G.E., Kunz R., Falck-Ytter Y., Alonso-Coello P., et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008, 336(7650):924-926.
42. Hoekstra J., Bresser E.L., Smalberg J.H., Spaander M.C., Leebeek F.W., Janssen H.L. Long-term follow-up of patients with portal vein thrombosis and myeloproliferative neoplasms. J Thromb Haemost 2011, 9:2208-2214.
43. Sozer S., Fiel M.I., Schiano T., Xu M., Mascarenhas J., Hoffman R. The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood 2009, 113(21):5246-5249.
44. Rosti V., Villani L., Riboni R., Poletto V., Bonetti E., Tozzi L., et al. Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation. Blood 2013, 121(2):360-368.
45. Löfvenberg E., Wahlin A. Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea. Eur J Haematol 1988, 41(4):375-381.
46. Petti M.C., Latagliata R., Spadea T., Spadea A., Montefusco E., Aloe Spiriti M.A., et al. Melphalan treatment in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2002, 116(3):576-581.
47. Mesa R.A. How I treat symptomatic splenomegaly in patients with myelofibrosis. Blood 2009, 113(22):5394-5400.
48. Mesa R.A., Nagorney D.S., Schwager S., Allred J., Tefferi A. Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer 2006, 107(2):361-370.
49. Tefferi A., Mesa R.A., Nagorney D.M., Schroeder G., Silverstein M.N. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood 2000, 95(7):2226-2233.
50. Barosi G., Ambrosetti A., Buratti A., Finelli C., Liberato N.L., Quaglini S., et al. Splenectomy for patients with myelofibrosis with myeloid metaplasia: pretreatment variables and outcome prediction. Leukemia 1993, 7(2):200-206.
51. Barosi G., Ambrosetti A., Centra A., Falcone A., Finelli C., Foa P., et al. Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia Italian Cooperative Study Group on Myeloid with Myeloid Metaplasia. Blood 1998, 91(10):3630-3636.
52. Santos F.P., Tam C.S., Kantarjian H., Cortes J., Thomas D., Pollock R., et al. Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation. Leuk Lymphoma 2013, [Epub ahead of print].